Introduction {#acn3367-sec-0001}
============

Duchenne muscular dystrophy (DMD) is the most common inherited myopathy (1 in 5000 live births).[1](#acn3367-bib-0001){ref-type="ref"} Muscles in the hips, thighs, and shoulders are first affected followed by the arms, legs, and trunk. Patients ultimately lose independence in mobility. Outcome measures in clinical trials including the 6‐min walk test target the abilities of the lower limb function in ambulatory boys. These measures may not be applicable to patients who lose their independent mobility during the duration of the clinical trial. Functional measures assessing the upper limb performance in DMD are being developed.[2](#acn3367-bib-0002){ref-type="ref"}, [3](#acn3367-bib-0003){ref-type="ref"} Magnetic resonance imaging (MRI) allows a reliable and repeatable assessment of individual muscles. Few studies have focused on the MRI of forearm muscles in DMD.[4](#acn3367-bib-0004){ref-type="ref"}, [5](#acn3367-bib-0005){ref-type="ref"}, [6](#acn3367-bib-0006){ref-type="ref"} Quantitative MRI of the upper arm muscles has not been previously reported in this disease.

Individuals with DMD develop cardiomyopathy by age 18 years.[7](#acn3367-bib-0007){ref-type="ref"} Whereas corticosteroids and supportive measures have improved overall prognosis and lifespan, cardiomyopathy continues to be relentlessly progressive and has become a major cause of death.[8](#acn3367-bib-0008){ref-type="ref"} Recent guidelines emphasize the need for early diagnosis and aggressive treatment for cardiomyopathy in DMD.[9](#acn3367-bib-0009){ref-type="ref"} MRI is increasingly used to evaluate myocardial damage and ventricular function.[10](#acn3367-bib-0010){ref-type="ref"}, [11](#acn3367-bib-0011){ref-type="ref"} Pathological changes in progressive degeneration such as interstitial edema, fatty transformation, and fibrosis are shared between skeletal and cardiac muscle.[12](#acn3367-bib-0012){ref-type="ref"} The timing of disease in myocardium in relation to skeletal muscle of younger boys with DMD has not yet been delineated.

Methods {#acn3367-sec-0002}
=======

Participants and study design {#acn3367-sec-0003}
-----------------------------

In this cross‐sectional study, MRI was acquired in ambulatory DMD participants with mutations amenable to exon 51 skipping during first screening visit for a clinical trial evaluating an oligonucleotide therapy (NCT01462292) (Data S1). All DMD participants were on oral corticosteroids with a dose equivalent to prednisone 0.75 mg/kg per day, 11 patients were treated with prednisone only, and 1 patient with deflazacort only. The DMD participants were not on any cardiac‐protective therapy. The subjects did not report symptoms of cardiomyopathy such as shortness of breath, chest pain, fainting, dizziness, or swelling in the ankles and legs. The echocardiograms showed normal left ventricular ejection fraction (\>55%), end‐diastolic and end‐systolic volume, stroke volume, and mass normalized to body surface area. The DMD participants had no demonstrable weakness of the elbow flexion and extension by manual muscle strength testing. Age‐range‐matched healthy volunteer boys were recruited from the NIH Clinical Research Volunteer Program registry. All were asked to avoid any excessive physical activity beyond their normal levels for a week before the study visit. The study was registered on [clinicaltrials.gov](http://clinicaltrials.gov) (NCT01451281) and was in compliance with the NIH Privacy Act and approved by an NIH Institutional Review Board. Informed written assent and consent were obtained from each subject and parent or guardian.

MRI acquisition and analysis {#acn3367-sec-0004}
----------------------------

Cardiac and right upper extremity MRI was acquired on 1.5T scanners (Siemens Avanto or Espree, Erlangen, Germany). An 18‐element torso‐phased array coil was used for both cardiac and arm imaging. The upper arm was kept in an abducted position at the subject\'s side by the coil, which was partially wrapped around the torso and secured by the straps used to hold the coil in position. Imaging of the upper extremity was performed at the mid‐upper arm, defined on the humerus as the midpoint between the inferior edge of the trochlea and the humerus head. Myocardial and upper arm *T* ~1~ and *T* ~2~ were acquired with an ECG‐gated‐modified Look‐Locker method[13](#acn3367-bib-0013){ref-type="ref"} and a *T* ~2~‐prepared, steady‐state‐free precession method (no fat suppression).[14](#acn3367-bib-0014){ref-type="ref"} The fat and water fractions were acquired with a four‐point cardiac‐optimized Dixon method.[15](#acn3367-bib-0015){ref-type="ref"} Regions of interest (ROI) drawn for the biceps and triceps muscles in the six slices of the mid‐upper arm covering a distance of 36 mm. Myocardial ROIs were drawn to include the entire myocardium, but excluded the papillary muscles in mid‐ventricular short‐axis slices of the left ventricle (LV), which were identified based on the end‐diastolic image. All ROIs drawn manually as illustrated in Figure [1](#acn3367-fig-0001){ref-type="fig"} on Dixon images were aligned to *T* ~1~ and *T* ~2~ images so that the same regions were analyzed for quantitative measurements. The upper arm cross‐sectional area (CSA) was measured by manual planimetry. The LV size and function was assessed with cine MRI using manual planimetry by a cardiologist with expertise in cardiac MRI. All analyses were done by investigators blinded to other clinical information.

![Representative fat water images, and *T* ~1~‐ and *T* ~2~ *‐*parametric maps of the upper arm muscles and heart in a healthy volunteer (A and B) and a subject with Duchenne muscular dystrophy (DMD) (C and D). The biceps and triceps muscles are outlined on the fat and water images with regions of interest colored blue and green, respectively, but with white regions of interest on the *T* ~1~ *‐* and *T* ~2~‐parametric maps. There is increased fat signal from both muscles in a subject with DMD (C) than in a healthy volunteer (A). The red regions of interest delineate the location of the epicardial and endocardial borders of the left ventricular myocardium on the fat and water separation images. The green regions of interest delineate the location of the epicardial and endocardial borders of the left ventricular myocardium on the *T* ~1~ and *T* ~2~ maps. There is very little fat signal from the myocardium of a subject with DMD (D), which is similar to that in a healthy volunteer (B).](ACN3-3-948-g001){#acn3367-fig-0001}

Statistical analysis {#acn3367-sec-0005}
--------------------

The Mann--Whitney test was used in cross‐sectional comparisons. The level of significance was set at *P* \< 0.05. Pearson\'s correlation was used for continuous variables. Spearman\'s rank correlation was used for ordinal variables. Data analyses were done using Prism 6.0 (Graphpad Software, La Jolla, CA).

Results {#acn3367-sec-0006}
=======

The right upper arm and cardiac MRI were obtained in 12 ambulatory DMD participants (age range: 6--14 years) and 20 healthy volunteers (age range: 5--14 years). The median age of the DMD participants was younger than that of the healthy volunteers by 2 years (*P* = 0.06) (Table [1](#acn3367-tbl-0001){ref-type="table-wrap"}). The DMD participants were shorter, weighed less, and consequently had smaller body surface area (*P* \< 0.001) relative to the healthy volunteers (Table [1](#acn3367-tbl-0001){ref-type="table-wrap"}).

###### 

Demographics and MRI measures of the upper arm muscle and nonmuscle CSA and LV systolic function in DMD participants and the healthy volunteers

                                                                           DMD (*N* = 12) Median (IQR)   Healthy volunteer (*N* = 20) Median (IQR)   Mann--Whitney *P* value
  ------------------------------------------------------------------------ ----------------------------- ------------------------------------------- -------------------------
  Age (years)                                                              8.0 (2.75)                    10.0 (2.75)                                 0.06
  Height (cm)                                                              123.4 (12.6)                  145.2 (12.5)                                \<0.0001
  Weight (kg)                                                              30.7 (13.6)                   40.3 (13.7)                                 \<0.05
  Body mass index (kg/m^2^)                                                20.3 (6.6)                    17.3 (4.6)                                  0.06
  Body surface area (m^2^)                                                 1.0 (0.26)                    1.3 (0.25)                                  \<0.001
  Right upper arm CSA (cm^2^)[a](#acn3367-note-0003){ref-type="fn"}        36.0 (16)                     33.0 (18)                                   0.3
  Muscle (% of CSA)[a](#acn3367-note-0003){ref-type="fn"}                  43.0 (16)                     50.0 (12)                                   0.1
  Biceps CSA (cm^2^)[a](#acn3367-note-0003){ref-type="fn"}                 4.0 (1.6)                     4.5 (1.9)                                   0.2
  Triceps CSA (cm^2^)[a](#acn3367-note-0003){ref-type="fn"}                10.0 (5)                      10.0 (4)                                    0.3
  Nonmuscle soft tissue (% of CSA)[a](#acn3367-note-0003){ref-type="fn"}   53.0 (17)                     45.0 (10)                                   \<0.05
  Bone (% of CSA)[a](#acn3367-note-0003){ref-type="fn"}                    3.0 (1.6)                     6.0 (1.6)                                   \<0.0001
  Heart rate (beats/min)                                                   97.0 (15)                     79.0 (21)                                   \<0.001
  LV EF (%)                                                                60.0 (14.2)                   62.3 (7.2)                                  0.6
  LV EDVi (mL/m^2^)                                                        75.4 (14.2)                   75.3 (13.6)                                 0.6
  LV ESVi (mL/m^2^)                                                        30.3 (9.6)                    30.2 (5.8)                                  0.9
  LV ED mass (g/m^2^)                                                      44.4 (10)                     43.8 (16.5)                                 0.8
  SV index (mL/m^2^)                                                       44.0 (9)                      47.5 (10.2)                                 0.5
  Cardiac index (L/min per m^2^)                                           4.1 (1.1)                     3.8 (1.1)                                   \<0.05

MRI, magnetic resonance imaging; LV, left ventricular; DMD, Duchenne muscular dystrophy; IQR, interquartile range; CSA, cross‐sectional area; EF, ejection fraction; EDVi, end‐diastolic volume index; ESVi, end‐systolic volume index; ED, end diastolic; SV, stroke volume.

*N* = 19 healthy volunteers.

John Wiley & Sons, Ltd

The upper arm skeletal muscle MRI {#acn3367-sec-0007}
---------------------------------

Upper arm skeletal muscle MRI was evaluated in 12 DMD participants and 19 healthy volunteers. The upper arm MRI in one 7‐year‐old healthy volunteer was not suitable for quantitative analysis due to motion artifact. Upper arm and muscle CSA were similar between the DMD participants and the healthy volunteers. The fraction of the arm CSA comprising subcutaneous fat or connective tissue was larger and that of bone was smaller in DMD participants than in the healthy volunteers (Table [1](#acn3367-tbl-0001){ref-type="table-wrap"}). We found that median muscle fat fractions were higher in the biceps and triceps muscles of DMD participants than the healthy volunteers (20% vs. 9%, *P* \< 0.001, and 13% vs. 7%, *P* \< 0.0001, respectively; Fig. [2](#acn3367-fig-0002){ref-type="fig"}A); data from individual subjects are shown in Table S1. There was an age‐associated increase in muscle fat in the biceps muscle of DMD participants (Fig. [2](#acn3367-fig-0002){ref-type="fig"}B). The *T* ~1~ relaxation times were not significantly different in the biceps and triceps muscles between the groups (882 msec vs. 849 msec, *P* = 0.7, and 864 msec vs. 846 msec, *P* = 0.8, respectively). The median *T* ~2~ relaxation times were increased in both muscles of DMD participants compared to the healthy volunteers (37 msec vs. 31 msec, *P* \< 0.0001; Fig. [2](#acn3367-fig-0002){ref-type="fig"}C). The *T* ~2~ correlated with muscle fat (%) in DMD participants (*r* = 0.6, *P* \< 0.01).

![MRI quantification of muscle fat (%) and *T* ~2~ (msec) in the biceps and triceps muscles and the myocardium of the healthy volunteers (blue) and subjects with Duchenne muscular dystrophy (DMD) (red). (A) Median muscle fat (%) of the biceps and triceps muscles is significantly higher in DMD participants (*n* = 12) than in the healthy volunteers (*n* = 19). (B) Age correlation of the biceps muscle fat (%) in DMD participants. Horizontal dotted line represents the median value of the age‐range‐matched healthy volunteers. (C) Median muscle *T* ~2~ of the biceps and triceps muscles is significantly higher in DMD participants (*n* = 12) than in the healthy volunteers (*n* = 19). (D) The myocardial fat (%) in DMD participants (*n* = 12) is similar to the healthy volunteers (*n* = 20). (E) Median myocardial *T* ~1~ (msec) of DMD participants (*n* = 12) tended to be lower than that of the healthy volunteers (*n* = 18), although the difference is not statistically significant. The myocardial segments are numbered as in (F). (F) Median myocardial *T* ~2~ of the anteroseptal segment (6) is significantly lower in DMD participants (*n* = 10) than in the healthy volunteers (*n* = 16). The *T* ~2~ values in the anterior (1), anterolateral (2), inferolateral (3), inferior (4), and inferoseptal (5) myocardial segments of DMD participants are similar to that in healthy volunteers. Box and whiskers represent 5th--95th percentile values. Error bars in scatter plots represent median with interquartile range. \**P* \< 0.05, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001. Also, see Table S1.](ACN3-3-948-g002){#acn3367-fig-0002}

Cardiac MRI {#acn3367-sec-0008}
-----------

Subjects with DMD had higher heart rates (*P* \< 0.001) than healthy volunteers (Table [1](#acn3367-tbl-0001){ref-type="table-wrap"}). The MRI measures of LV systolic function and myocardial fat percentage were obtained in 12 DMD participants and 20 healthy volunteers. The LV mass, ejection fraction, and end‐diastolic and end‐systolic volumes adjusted for body surface area were not different between the groups. Cardiac index was normal for age[16](#acn3367-bib-0016){ref-type="ref"} in both groups, although higher in subjects with DMD (*P* = 0.03; Table [1](#acn3367-tbl-0001){ref-type="table-wrap"}), which may be partly related to tachycardia. Myocardial fat fractions were similar between the groups (Fig. [2](#acn3367-fig-0002){ref-type="fig"}D). Myocardial *T* ~1~ relaxation times in two healthy volunteers and myocardial *T* ~2~ relaxation times in four healthy volunteers and two DMD participants were not measured due to poor signal‐to‐noise ratio of the MR images. We found that median myocardial *T* ~1~ values were lower in DMD participants than healthy volunteers, but with overlapping range of values in both groups (Fig. [2](#acn3367-fig-0002){ref-type="fig"}E). Myocardial *T* ~2~ relaxation times of the anteroseptal segment were lower in DMD participants than healthy volunteers (42 msec vs. 45 msec, *P* = 0.04; Fig. [2](#acn3367-fig-0002){ref-type="fig"}F, Table S1).

Discussion {#acn3367-sec-0009}
==========

We simultaneously assessed and analyzed MRI biomarkers of muscle fat percentage and muscle *T* ~1~ and *T* ~2~ relaxation times in the upper arm skeletal muscles and heart of ambulatory boys with DMD at a stage when they did not yet have symptomatic heart disease. We found that the MRI abnormalities were readily apparent in the biceps and triceps muscles but not heart of subjects with DMD.

Our DMD participants did have sinus tachycardia which can be an independent risk factor for cardiac failure.[17](#acn3367-bib-0017){ref-type="ref"} In patients with DMD, dilated cardiomyopathy is the most common cardiac manifestation and is associated with high risk of heart failure and premature death once the patient becomes symptomatic. Recognition of cardiac symptoms may occur at a later stage in the disease course of DMD due to physical inactivity and other respiratory symptoms that may obscure the diagnosis.[18](#acn3367-bib-0018){ref-type="ref"} Early noninvasive diagnosis could promote early treatment and prevention of heart failure in patients.[19](#acn3367-bib-0019){ref-type="ref"}

MRI allows accurate assessment of composition of the myocardium and correlation with LV function in DMD.[18](#acn3367-bib-0018){ref-type="ref"} We found that MRI measures of LV systolic function were normal in the relatively young DMD participants (75% of patients \<10 years old). A recent study reported decreased myocardial *T* ~2~ in relatively older patients (age range 8--27 years) with LV ejection fraction lower than controls.[20](#acn3367-bib-0020){ref-type="ref"} Whether evidence of decreased in myocardial *T* ~1~ and *T* ~2~ relaxation times in our younger DMD cohort represent early changes in fatty infiltration or fibrosis remains to be confirmed in future studies.

Gadolinium assessment of myocardial fibrosis and extracellular volume fraction may be useful in predicting heart failure from LV diastolic dysfunction.[21](#acn3367-bib-0021){ref-type="ref"}, [22](#acn3367-bib-0022){ref-type="ref"} In this study gadolinium exposure was specifically excluded to minimize chances of introducing adverse renal complications not attributable to the oligonucleotide therapy in DMD participants who were participating in a clinical trial.

In DMD, MRI assessment of the upper limb muscles and heart is applicable across different stages of the disease, from young boys to nonambulant individuals, because upper limbs and heart are affected at a later stage compared to lower limbs. Natural history studies are needed to better understand the relation between the disease progression in skeletal muscles of the upper and lower limbs and in heart of patients, which is not yet clearly understood. MRI biomarkers of muscle fat percentage are responsive to disease progression in the lower limb and forearm muscles of patients with DMD.[4](#acn3367-bib-0004){ref-type="ref"}, [23](#acn3367-bib-0023){ref-type="ref"}, [24](#acn3367-bib-0024){ref-type="ref"} Moreover, muscle fat percentage changes were detected in the lower limb muscles of younger patients who were functionally stable or showed improvement in the functional outcome measures over 1 year.[23](#acn3367-bib-0023){ref-type="ref"}, [25](#acn3367-bib-0025){ref-type="ref"} Imaging fatty replacement in the myocardium may be a noncontrast method of assessing the disease state of the myocardium in individuals with DMD. In this study, the cardiac‐optimized MRI methods detected increased muscle fat fraction and edema in the upper arm muscles but not in the myocardium of DMD participants. Thus, our young DMD participants had limited abnormalities in the myocardium compared to the upper arm muscles.

Ancillary findings of this study are lower humeral CSA and higher nonmuscle soft tissue CSA in the DMD participants than in the healthy volunteers. Lower bone mass and higher fat mass have been reported in patients with DMD. The compromised state of the muscle--bone unit, defined as the bone mineral content per CSA of local muscle, likely influences the bone health and increases fracture risk in DMD.[26](#acn3367-bib-0026){ref-type="ref"} MRI has the potential to monitor the bone health in addition to the state of skeletal muscle in DMD.[27](#acn3367-bib-0027){ref-type="ref"}

This study was done at a single site, although the participants were recruited from across the country. In addition, specific eligibility criteria of the clinical trial affected the sample size of the DMD participants. We were limited by having patients with dystrophin mutations potentially correctable by exon 51 skipping, which was an absolute requirement for their participation in the clinical trial of an oligonucleotide therapy. This may have introduced a bias as specific dystrophin mutations likely affect the severity of cardiac disease in patients with DMD.[28](#acn3367-bib-0028){ref-type="ref"} Our study design as a part of the clinical trial did not include functional assessments of upper limb muscles. Future studies are needed to investigate the relation between the imaging biomarkers and their value in predicting clinically meaningful milestones such as time to loss of self‐care, hospitalization for heart failure, and survival.

An objective of this study was to detect subclinical abnormalities of the heart using MRI techniques amenable to routine clinical application. Fat fraction was measured with cardiac optimized Dixon methods,[15](#acn3367-bib-0015){ref-type="ref"} the fat image and the water image were created from the same raw data and the same ROI was used to make both measurements simultaneously. Whereas these methods should minimize measurement variability, errors could still occur related to where the edges of the ROI are drawn, partial volume errors, and image artifacts. The percent myocardial fat in healthy volunteers was considerably higher than the \~0.5% measured by MR spectroscopy.[29](#acn3367-bib-0029){ref-type="ref"} The cardiac‐optimized fat water sequence had to be feasible within a breath hold, which limited the amount of data that can be acquired thus compromising signal‐to‐noise ratio. The technique may be modified to include signal averaging and motion correction or navigator technology to allow higher fidelity measurements.

In conclusion, we show the feasibility of imaging the upper arm skeletal muscles and heart of young boys with DMD and age‐range‐matched healthy volunteers using the same MR sequences applicable in clinical setting. Simultaneous assessments provide clinically useful tests for monitoring disease progression and therapeutic response in the heart and upper arm muscles in patients with DMD. These tests are also pertinent to other muscular dystrophies affecting heart.
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**Table S1.** MRI measures of the upper arm skeletal muscle and heart in DMD participants and the healthy volunteers. The data from Figure [1](#acn3367-fig-0001){ref-type="fig"} in each participant are shown.

###### 

Click here for additional data file.

###### 

**Data S1.** The subject eligibility and recruitment, and the inclusion and exclusion criteria for the NIH DMD Imaging Study

###### 

Click here for additional data file.
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